ACTRN12608000174381招募中不适用
A pilot study of dendritic cell (DC) vaccination using DCs pulsed with cell derived tumour antigen for stage IV melanoma following immune modulatory doses of chemotherapy to determine safety and tolerability.
niversity of Queensland0 个研究点目标入组 20 人开始时间: 2008年4月9日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 16 Years 至 ot stated(—)
- 性别
- All
入选标准
- •All subjects
- •1. Patients with metastatic stage IV metastatic melanoma not curable with standard therapy (radiotherapy or chemotherapy) and/or in whom standard therapy does not have proven survival benefits. This is relevant to the clinical state of the patient at the time of enrolment.
- •2. Written informed consent
- •3. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 (see Appendix 2)
- •4. Subject judged to be able to safely undergo leukapheresis
- •5. Age > 16.
- •6. Life expectancy estimated to be greater than 4 months
排除标准
- •1. Any concurrent therapy with possible activity against the patient’s malignancy with the exception of aminobisphosphonates
- •(local radiotherapy on lesions not essential for study evaluation is allowed)
- •2. Concurrent therapy with any agent known to have immune modulating activity
- •3. Any therapy with possible activity against the patient’s malignancy in the month preceding administration of first dose of study therapy
- •4. Patient unable to undergo leukapheresis due to serious co-existing medical conditions
- •(particularly cardiac or cardiovascular) or for other reasons
- •5. ECOG > 2
- •6. Pregnant or breast feeding or at risk for becoming pregnant within 3 months of enrolment
- •7. HIV, Hepatitis B or Hepatitis C positive
- •8. Patients who need immediate therapy because of a disease related complication or in whom a complication is predicted on clinical suspicion, and for whom some standard therapy is available and appropriate in the clinical condition. This does not apply to disease symptoms for which non disease specific therapy (e.g. analgesia) would be routinely offered. Patients excluded because of these criteria can become eligible after the immediate medical need has been fully treated with standard therapy and one month has elapsed.
研究者
相似试验
撤回
1 期
Phase I trial of dendritic cell vaccination and celecoxib with postoperative radiotherapy and temozolomide for treatment of malignant glioma.Malignant gliomaCancer - BrainACTRN12609000736246Queensland Institute of Medical Research10
招募中
不适用
Clinical trial evaluating dendritic cell vaccination as an adjuvant immunotherapy in patients with pancreatic cancerPancreatic cancerJPRN-UMIN000009994Yokohama City University, Gastroenterological Surgery20
已完成
不适用
Clinical study of dendritic cell vaccine combined with transarterial embolization for patients with hepatocellular carcinomahepatocellular carcinomaJPRN-UMIN000012702Faculty of Medical Sciences, University of Fukui3
进行中(未招募)
1 期
Dendritic cell vaccine immunotherapy in paediatric high grade gliomaPaediatric High grade glioma, excluding brain stem gliomasMedDRA version: 16.1 Level: PT Classification code 10065443 Term: Malignant glioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018447-34-GBGreat Ormond Street Hospital for Children NHS Trust20
已完成
1 期
Clinical study of Dendritic Cell Vaccine in patients with Gastroenterological Cancer and Hepato-Biliary-Pancreatic Cancer.Esophageal cancer, Stomach cancer, Colon cancer, HCC, ICC, Bile duct cancer, pancreatic cancerJPRN-UMIN000005820Department of Gastroenterological Surgery, Tokyo Women's Medical University100
